stockportfolio.pro
Stocks / BIO vs RGEN
BIO vs RGEN
Bio-Rad Laboratories, Inc. and Repligen Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bio-Rad Laboratories, Inc. (BIO) | Repligen Corporation (RGEN) | |
|---|---|---|
| Market cap | $7.8B | $7.4B |
| Revenue (latest FY) | $2.58B | $738.26M |
| Net income (latest FY) | $759.90M | $48.89M |
| Revenue growth (5y CAGR) | 0.3% | 15.0% |
| Net margin | 29.4% | 6.6% |
| Return on equity | 10.2% | 2.3% |
| P/E ratio | 48.8 | 144.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 9 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BIO — free Open RGEN — freeFrequently asked questions
Which is bigger, BIO or RGEN?
Bio-Rad Laboratories, Inc. is larger by market capitalization — $7.8B versus $7.4B.
Which grows faster, BIO or RGEN?
Over the last five fiscal years, Repligen Corporation grew revenue faster — 15.0%/yr versus 0.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.